The Board of Directors of Syngene International Limited, at its meeting held on January 22, 2026, approved the un-audited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025. For the quarter ended December 31, 2025 (Q3 FY26), the company reported a consolidated revenue from operations of ₹9,136 Million, representing a slight increase of 0.33% from ₹9,106 Million in the previous quarter (Q2 FY26). However, compared to the corresponding quarter of the previous year (Q3 FY25), revenue saw a decline of 3.23% from ₹9,441 Million. The Net Profit for Q3 FY26 stood at ₹741 Million, showing an 11.43% growth from ₹665 Million in Q2 FY26, but experienced a significant 43.43% decrease compared to ₹1,310 Million in Q3 FY25.

Syngene International Limited is a leading global contract research, development, and manufacturing organization (CRDMO) providing integrated scientific services from early discovery to commercial supply. The company serves various sectors, including pharmaceutical, biotechnology, nutrition, and specialty chemicals. In recent 2025 updates, Syngene extended its strategic collaboration with Bristol Myers Squibb through to 2035, expanding the scope of its integrated services. Additionally, the company was recognized by TIME magazine as one of the “World’s Best Companies in Sustainable Growth” in 2025. Notable institutional investors include the Government of Singapore and the Government Pension Fund Global, while prominent individual investors include Kiran Mazumdar-Shaw.